NCT05861557尚未招募2 期
A Prospective Phase II Trial to Evaluate the Safety and Efficacy of Neoadjuvant Radiotherapy Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- Major pathological response (MPR)
研究概览
简要总结
This is a phase II study. Twenty-three patients with locally advanced head and neck squamous cell carcinoma were planned to be enrolled to assess the efficacy and safety of neoadjuvant immunotherapy combined with radiotherapy.
详细描述
After receiving one cycle of immunotherapy, the subjects underwent SBRT radiotherapy to the lesion, followed by another cycle of immunotherapy. Surgery was performed 3-6 weeks later, and subsequent radiotherapy or chemoradiotherapy was decided after surgery based on pathological examination. Immunotherapy was maintained for 6 months. Treatment continued until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by the principal investigator, whichever occurred first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign informed consent;
- •Age ≥ 18 years, regardless of gender;
- •Histology or cytology confirmed head and neck squamous cell carcinoma, HNSCC (Oral cavity, oropharynx, larynx and hypopharynx), and previously untreated;
- •Imaging confirmed that HNSCC was locally advanced and operable;
- •Imaging confirmed no metastasis;
- •ECOG physical status score 0-1;
- •Life expectancy at least 24 weeks;
- •Have measurable lesions;
- •Good function of other major organs (liver, kidney, blood system, etc.):
- •Absolute neutrophil count ((ANC) ≥ 1.0×10^9), platelet (≥ 80×10^9), hemoglobin (≥ 80g/L). Blood biochemical examination must meet: serum creatinine (Cr) ≤1.5 times the upper limit of normal (ULN) or endogenous creatinine clearance ≥60mL/min; TBIL≤1.5×ULN; ALB≥30g/L; ALT and AST≤ 3.0×ULN; TSH≤1.5×ULN;
- •Female patients with fertility must undergo a pregnancy test (serum or urine) within 14 days before enrollment, and the result is negative, and they voluntarily adopt appropriate methods of contraception during the observation period and within 120 days after the last administration; Male patients must voluntarily take effective contraceptive measures from the start of treatment until 120 days after the last administration.
排除标准
- •Pregnant or breastfeeding, or planning to become pregnant during the study period
- •Patients with active autoimmune diseases or immunodeficiency diseases, including but not limited to myasthenia gravis, interstitial pneumonia, enteritis, autoimmune hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, positive HIV test or a history of the above diseases, or a history of organ transplantation;
- •Receiving systemic immunosuppressive drugs within 2 weeks before starting study treatment, or anticipating the need for systemic immunosuppressive drugs during study treatment;
- •Received systemic immunostimulants (including but not limited to interferon or interleukin-2 [IL-2]) within 4 weeks before starting study treatment;
- •History of other malignant tumors within the past 5 years, except cured cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ;
- •Serious cardiovascular disease, unstable arrhythmia, or unstable angina pectoris within 3 months before starting study treatment;
- •The subject has an active infection or infectious disease, or unexplained fever (body temperature > 38.5℃) during screening and before the first dose;
- •Patients who have received therapeutic oral or intravenous antibiotics within 2 weeks prior to starting study treatment; patients receiving prophylactic antibiotic therapy (e.g., prophylaxis for urinary tract infection or chronic obstructive pulmonary - Untreated active hepatitis;
- •Receiving immunotherapy such as PD-1/L1 antibody or CTLA-4 antibody within 4 weeks before enrollment;
- •Received chemotherapy or targeted therapy within 4 weeks before enrollment;
- •The subject has participated in or completed other clinical trials within 4 weeks before enrollment;
- •Subjects may need to receive other anti-tumor therapy during the study;
- •Subjects may need to receive a vaccine during the study or within 4 weeks prior to enrollment.
研究组 & 干预措施
Experimental arm
Experimental
Toripalimab + SBRT radiotherapy
干预措施: Stereotactic Body Radiation Therapy (SBRT) (Radiation)
Experimental arm
Experimental
Toripalimab + SBRT radiotherapy
干预措施: Toripalimab (Drug)
结局指标
主要结局
Major pathological response (MPR)
时间窗: up to 6 months
Percentage of Participants with MPR. MPR is defined as \> 90 percent decrease in viable tumor.
次要结局
- Pathological Complete Response (pCR)(up to 6 months)
- Quality of life questionnaires(up to 1 year)
- Frequency and severity of perioperative adverse events(up to 6 months)
研究者
Zhou Huifang
Director of Otorhinolaryngology Department
Tianjin Medical University General Hospital
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
MIT-001 for Prevention of CCRT-Induced OM in HNSCC PatientsHead and Neck Squamous Cell CarcinomaOral MucositisNCT04651634MitoImmune Therapeutics60
已完成
2 期
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT02823574Bristol-Myers Squibb425
招募中
2 期
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCHead and Neck Squamous Cell CarcinomaOral CancerNCT05941338Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University100
已完成
2 期
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNCT05156970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University81
招募中
不适用
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCCSquamous Cell Carcinoma of Head and NeckNCT04688528Universitaire Ziekenhuizen KU Leuven147